报告人：Dr. Colonno （Executive VP and Chief Scientific Officer）

Assembly Biosciences Inc

题　目：Targeting Core Protein with CpAMs to Achieve Higher HBV Cure Rates

时　间：2018年5月18日11:00-12:00

地　点：药学楼241会议室 

Dr. Colonno is an internationally recognized expert with nearly 40 years of experience in antiviral drug discovery and development. He has served in leadership roles at Presidio Pharmaceuticals, Bristol-Myers Squibb, and Merck, and has played critical roles in the discovery and development of several approved drugs for HIV, HBV and HCV, including entecavir (Baraclude) for HBV and atazanavir (Reyataz) for HIV. Dr. Colonno has presented extensively at international meetings and has co-authored more than 160 scientific articles.